Use of Selective Serotonin Reuptake Inhibitors During Pregnancy and Risk of Major and Cardiovascular Malformations: An Update

被引:21
作者
Tuccori, Marco [1 ]
Montagnani, Sabrina [2 ]
Testi, Arianna [3 ]
Ruggiero, Elisa [4 ]
Mantarro, Stefania [2 ]
Scollo, Carla [2 ]
Pergola, Alessandra [2 ]
Fornai, Matteo [5 ]
Antonioli, Luca [2 ]
Colucci, Rocchina [5 ]
Corona, Tiberio [3 ]
Blandizzi, Corrado [2 ,5 ]
机构
[1] Univ Hosp Pisa, Tuscan Reg Ctr Pharmacovigilance, Pharmacol Unit, I-56126 Pisa, Italy
[2] Univ Pisa, Interdept Ctr Res Clin Pharmacol & Expt Therapeut, Pisa, Italy
[3] Reg Hlth Syst, Pharmaceut Unit, Pisa, Italy
[4] Univ Hosp Pisa, Pharmaceut Unit, Pisa, Italy
[5] Univ Pisa, Dept Internal Med, Div Pharmacol, Pisa, Italy
关键词
selective serotonin reuptake inhibitors; paroxetine; major malformations; cardiovascular malformations; pregnancy; CONGENITAL-MALFORMATIONS; MATERNAL USE; ANTIDEPRESSANT DRUGS; 1ST-TRIMESTER EXPOSURE; PRENATAL EXPOSURE; 1ST TRIMESTER; IN-UTERO; PAROXETINE; DEPRESSION; FLUOXETINE;
D O I
10.3810/pgm.2010.07.2175
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
General consensus exists about the need to avoid drug intake as much as possible during pregnancy due to the lack of thorough evidence about the safety of pharmacologic treatments during gestation for both mothers and fetuses. In this respect, the overall safety profile of selective serotonin reuptake inhibitors (SSRIs) in pregnancy remains unclear. This article reviews current evidence about the safety of each SSRI during pregnancy in order to describe their specific teratogenic potential, with a particular focus on major and cardiovascular malformations, and to verify whether such toxicity can be considered as a class effect. The literature review included controlled studies and meta-analyses (retrieved using PsychINFO, EMBASE, and Medline from January 1966 to May 2010) from which the risk of major and/or cardiovascular malformations associated with a specific SSRI (ie, fluoxetine, paroxetine, sertraline, citalopram, escitalopram, and fluvoxamine) could be estimated. Although there is evidence to support the association between birth defects and first-trimester exposure to paroxetine, findings from the studies reviewed suggest a teratogenic potential of the whole SSRI class, consistent with preclinical evidence. These teratogenic effects are mainly in the heart region, and they are often described as septal defects. It may be suggested that the higher frequency of teratogenic effects reported for paroxetine might depend on specific pharmacologic features of this drug compared with other SSRIs, although it is difficult to test this hypothesis. It is noteworthy that current evidence on SSRI teratogenicity stems from studies affected by several methodological weaknesses (ie, lack of investigations using control groups of untreated depressed mothers, confounding by indication, and recall bias). Accordingly, we are not yet able to rule out the possibility that positive associations, as determined in some studies, result from analyses of poor quality.
引用
收藏
页码:49 / 65
页数:17
相关论文
共 78 条
  • [1] Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies
    Addis, A
    Koren, G
    [J]. PSYCHOLOGICAL MEDICINE, 2000, 30 (01) : 89 - 94
  • [2] Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects
    Alwan, Sura
    Reefhuis, Jennita
    Rasmussen, Sonja A.
    Olney, Richard S.
    Friedman, Jan M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (26) : 2684 - 2692
  • [3] Point prevalence of psychiatric disorders during the second trimester of pregnancy:: A population-based study
    Andersson, L
    Sundström-Poromaa, I
    Bixo, M
    Wulff, M
    Bondestam, K
    Åström, M
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 189 (01) : 148 - 154
  • [4] Quantitative analysis of sponsorship bias in economic studies of antidepressants
    Baker, CB
    Johnsrud, MT
    Crismon, ML
    Rosenheck, R
    Woods, SW
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 2003, 183 : 498 - 506
  • [5] First-Trimester Use of Paroxetine and Congenital Heart Defects: A Population-Based Case-Control Study
    Bakker, Marian K.
    Kerstjens-Frederikse, Wilhelmina S.
    Buys, Charles H. C. M.
    de Walle, Hermien E. K.
    de Jong-van den Berg, Lolkje T. W.
    [J]. BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2010, 88 (02) : 94 - 100
  • [6] Paroxetine and congenital malformations:: Meta-analysis and consideration of potential confounding factors
    Bar-Oz, Benjamin
    Einarson, Thomas
    Einarson, Adrienne
    Boskovic, Radinka
    O'Brien, Lisa
    Malm, Heli
    Berard, Anick
    Koren, Gideon
    [J]. CLINICAL THERAPEUTICS, 2007, 29 (05) : 918 - 926
  • [7] Evidence of cost-effective treatments for depression: a systematic review
    Barrett, B
    Byford, S
    Knapp, M
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2005, 84 (01) : 1 - 13
  • [8] Prescribing patterns of antidepressants in europe: Results from the Factors Influencing Depression Endpoints Research (FINDER) study
    Bauer, Michael
    Monz, Brigitta U.
    Montejo, Angel L.
    Quail, Deborah
    Dantchev, Nicolas
    Dernyttenaere, Koen
    Garcia-Cebrian, Ana
    Grassi, Luigi
    Perahia, David G. S.
    Reed, Catherine
    Tylee, Andre
    [J]. EUROPEAN PSYCHIATRY, 2008, 23 (01) : 66 - 73
  • [9] The identification of depression and the coverage of antidepressant drug prescriptions in Italian general practice
    Bellantuono, C
    Mazzi, MA
    Tansella, M
    Rizzo, R
    Goldberg, D
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2002, 72 (01) : 53 - 59
  • [10] First trimester exposure to paroxetine and risk of cardiac malformations in infants:: The importance of dosage
    Berard, Anick
    Ramos, Elodie
    Rey, Evelyne
    Blais, Lucie
    St. Andre, Martin
    Oraichi, Driss
    [J]. BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2007, 80 (01) : 18 - 27